New Drug From Daiichi Sankyo Boosts Japan's OTC Market
This article was originally published in PharmAsia News
Executive Summary
In 2007, the Japanese OTC market grew by 2.3 percent to ¥700 billion, a reversal from a downward trend in recent years. New drugs such as Daiichi Sankyo's Transino contributed to the growth. A liver spots improving drug, Transino has activated the market for products treating pigment spots with sales increasing from ¥10 billion to ¥17 billion. Next year, Tokyo based SSP, a subsidiary of Boehringer Ingelheim, will market drugs made of western herbs such as gingko biloba and grape leaves. Taisho Pharmaceuticals also signed contacts with a German company to introduce similar products. (Click here for more - Japanese language